Volume 43, Issue 4 pp. 548-549
Short Communication

The Adipokine Visfatin is Markedly Elevated in Obese Children

Dominik G. Haider

Dominik G. Haider

Department of Clinical Pharmacology, Medical University of Vienna

Search for more papers by this author
Gregor Holzer

Gregor Holzer

Institute for Medical and Chemical Laboratory Diagnostics

Search for more papers by this author
Georg Schaller

Georg Schaller

Department of Clinical Pharmacology, Medical University of Vienna

Search for more papers by this author
Daniel Weghuber

Daniel Weghuber

Department of Pediatrics, Division of Nutrition and Metabolism, Medical University of Vienna

Search for more papers by this author
Kurt Widhalm

Kurt Widhalm

Department of Pediatrics, Division of Nutrition and Metabolism, Medical University of Vienna

Search for more papers by this author
Oswald Wagner

Oswald Wagner

Institute for Medical and Chemical Laboratory Diagnostics

Search for more papers by this author
Stylianos Kapiotis

Stylianos Kapiotis

Institute for Medical and Chemical Laboratory Diagnostics

Search for more papers by this author
Michael Wolzt

Corresponding Author

Michael Wolzt

Department of Clinical Pharmacology, Medical University of Vienna

Address correspondence and reprint requests to Dr Michael Wolzt, Medical University of Vienna, Department of Clinical Pharmacology, General Hospital of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria (e-mail: [email protected]).Search for more papers by this author
First published: 01 October 2006
Citations: 79

ABSTRACT

Objective:

The insulin-mimetic adipocytokine visfatin has been linked to adiposity and the metabolic syndrome.

Design

Cross-sectional study.

Subjects:

Eighty-three nondiabetic obese children and 40 healthy controls.

Measurements:

We analyzed plasma visfatin concentrations to assess whether this adipokine is associated with adiposity.

Results:

Plasma visfatin concentrations were nearly 2-fold higher in obese children (mean, 1.1 ng/mL; 95% CI, 0.2-6.6) than in controls (0.6 ng/mL, 95% CI, 0.6 to 0.6; P < 0.001). No relationship was detectable between visfatin and other subject characteristics, hsCRP or the lipid profile.

Conclusions:

Visfatin may be involved in the development of metabolic derangements in obese children.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.